Longeveron touts PhIIa Alzheimer's data, but drug's future remains murky
Longeveron released an update from a small Phase IIa Alzheimer’s study Thursday morning, claiming to show a win at the drug’s low dose. But questions …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.